Login to Your Account

In The Clinic NEWS

DUBLIN – Top-line data indicate the optimal dose of Poxel SA's first-in-class diabetes drug imeglimin hit the primary endpoint of a phase IIb dose-finding study in 382 patients with type 2 diabetes, with an average reduction in glycosylated hemoglobin (HbA1c) levels of 0.63 percent.

HONG KONG – The R&D arm of a China-based health care group owned by the multinational conglomerate Hutchison Whampoa Ltd. (HK:13) has moved its leading oncology candidate into phase III.

Ending the year in a much better position than it started, Chemocentryx Inc. reported positive data from its 52-week phase II study of CCR2 inhibitor CCX140 in diabetic nephropathy (DN), positioning the drug for phase III development and, hopefully, a partnership.

More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: